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Radovits3, Csaba Mátyás3, Attila Oláh3, Lenke K. Laurik2, Gábor M. Somfai2, Béla Merkely3, 
Ágoston Szél1 & Ákos Lukáts1
In diabetes, retinal dysfunctions exist prior to clinically detectable vasculopathy, however the 
pathology behind these functional deficits is still not fully established. Previously, our group published 
a detailed study on the retinal histopathology of type 1 diabetic (T1D) rat model, where specific 
alterations were detected. Although the majority of human diabetic patients have type 2 diabetes 
(T2D), similar studies on T2D models are practically absent. To fill this gap, we examined Zucker Diabetic 
Fatty (ZDF) rats - a model for T2D - by immunohistochemistry at the age of 32 weeks. Glial reactivity 
was observed in all diabetic specimens, accompanied by an increase in the number of microglia cells. 
Prominent outer segment degeneration was detectable with changes in cone opsin expression pattern, 
without a decrease in the number of labelled elements. The immunoreactivity of AII amacrine cells was 
markedly decreased and changes were detectable in the number and staining of some other amacrine 
cell subtypes, while most other cells examined did not show any major alterations. Overall, the retinal 
histology of ZDF rats shows a surprising similarity to T1D rats indicating that despite the different 
evolution of the disease, the neuroretinal cells affected are the same in both subtypes of diabetes.
Diabetes and its related complications including retinopathy cause a great social and economic burden globally, 
with a pandemic-like increase in the number of patients affected. Today, 415 million people are estimated to have 
diabetes worldwide1, among them type 2 diabetes (T2D) accounts for approximately 90% of the cases. Diabetic 
retinopathy is affecting one-third of the people living with diabetes1 with approximately 5 million cases of blind-
ness worldwide that can be attributed to this disease2.
The pathophysiology of diabetic retinopathy is complex. Besides the clinically detectable vascular alterations 
like microaneurysms, haemorrhages, vascular leakage and neovascularization it also includes neural retinal 
components3. Neuroretinal pathology may be represented by functional deficits like abnormalities of elect-
roretinographic (ERG) data and contrast sensitivity. Such impairments have been demonstrated in both animal 
models and human diabetic patients earlier than the appearance of funduscopically detectable vascular signs4, 5. 
Furthermore, these functional alterations may progress together with vascular retinopathy, or may even predict 
its progression6. Exploring the underlying mechanisms may open new perspectives in understanding the patho-
mechanism of the disease.
Similarly to other reports7–12 our previous studies13, 14 have demonstrated that in experimentally induced type 
1 diabetic (T1D) rats, several cell types of the retina, including astrocytes, Müller glia cells, photoreceptors, retinal 
pigment epithelium (RPE), amacrine and ganglion cells are already affected, even prior to significant apoptosis or 
clinically detectable vasculopathy.
In contrast to these observations, there is much less information on the early neuroretinal alterations in T2D 
models15. As the vast (and increasing) majority of human diabetic patients have T2D, it could be of particular 
interest.
Several T2D rat models such as ZDF, OLETF, SDT rats etc16. has become available in the past decades. Most 
of these models carry mutations in a single or multiple genes, related to obesity or insulin resistance, and reca-
pitulate some, but never all features of human T2D16–18. Due to a mutation in the leptin receptor gene, ZDF fa/fa 
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rats become obese, develop hyperglycaemia, hyperlipidaemia and early hyperinsulinemia on a high-fat diet by 12 
weeks of age. By postnatal week 20, with continuously high glucose levels, ZDF rats become insulinopenic with 
markedly reduced insulin levels19. Thus, diabetes in ZDF rats has common general metabolic characteristics with 
the human T2D20.
Although the development of vasculopathy in the retina is not specific to either T1D or T2D and there are no 
noteworthy clinical differences regarding the vascular lesions themselves21, 22, early retinopathy could be a differ-
ent issue. Elevated insulin levels, insulin resistance, obesity and the initially moderate rise of blood glucose levels 
in T2D are amongst the factors that need to be considered during evaluation. Insulin, for example, is considered 
as one of the key factors in the development and surviving of the cone and rod outer segment23, 24. It is possible 
therefore, that T2D rat models will show differences in the type of retinal cells affected or in the rate of damage. 
Comparing the retinas of T1D and T2D rat models could help to elucidate the role of insulin signalling in the 
development of histopathological changes in the retina.
In order to examine this possibility, in this report, we aimed to give a detailed qualitative and quantitative 
description on the early histopathological changes in the retina of ZDF rats and compare our results with pre-
vious studies dealing with experimentally induced T1D rats13, 14. Overall, we demonstrate here that the retinal 
histopathology of ZDF rats shows a surprising similarity to streptozotocin (STZ)-induced T1D rats. Thus, despite 
the different evolution of the disease, the neuroretinal cells affected are the same in both subtypes of diabetes, 
suggesting that most of the changes are probably the consequences of the high glucose levels whereas altered 
insulin signalling may play a less prominent role in the development of neural alterations. Preliminary results of 
this study have already been published in the form of an abstract25.
Results
Body weight and blood glucose levels. There was no significant difference in body weight between lean 
(421.3 ± 21.6 g) and diabetic animals (400.3 ± 50.2 g) at the time of euthanasia. The blood glucose levels remained 
normal throughout the complete observation period for lean animals (except for the values during anaesthesia) 
while for diabetic specimens they were significantly higher even at week 7, continued to rise till week 12 and 
remained elevated thereafter till euthanasia. Changes of blood glucose levels are demonstrated in Fig. 1. The 
blood glucose levels detected by us were in the middle of the “expected” range published by the supplier (Charles 
Rivers26). Detailed list of the appropriate p values and the results of the comparison within the same group at 
different postnatal ages are given in Supplementary material, Table S1.
Apoptosis and thickness measurements. There was a slight but significant increase in thickness of the 
whole retina (ILM-OLM) in all retinal positions and in ONL thickness in the inferior retinal half in diabetic ZDF 
rats compared to controls (Fig. 2a,b), probably due to oedema formation. Detailed list of the appropriate p values 
and the results of the comparison within the same group at different retinal locations are given in Supplementary 
material, Tables S2 and S3. Retinal thickness may remain normal or increase even in case of significant cell loss 
due to intracellular oedema formation that is known to occur in diabetes27. In order to exclude this possibility, 
we also attempted two other methods to evaluate the actual number of cell types. (1) In the ONL, nuclei are 
typically arranged in columns on well oriented sections; therefore, we counted the average number of nuclei per 
column in the same regions where the thickness measurements were performed. No significant difference was 
detectable (Fig. 2c, Table S4). (2) We also counted the number of immunohistochemically labelled elements on 
vertical sections. The results are detailed below in the subsequent paragraphs but in brief, they also exclude any 
major cell loss.
In line with this, we detected no increase in the number of apoptotic cells in TUNEL assays. Representative 
pictures of TUNEL labelled control and diabetic retinas are shown in Supplementary material, Fig. S5. The 
average number of apoptotic cells in the control specimens was 4.1 ± 3.05 per retina vs. 2.4 ± 1.6 in diabetic 
Figure 1. Blood glucose levels of lean and diabetic animals measured in different postnatal ages. From the  
7th week till the end of the observation period (time of anaesthesia, 32nd week (32/Anest)) blood glucose levels 
were significantly higher in diabetic specimens compared to controls. *p < 0.05.
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specimens, significantly lower in diabetic specimens (p: 0.02). Overall, we can conclude that the diabetic retinas 
were inspected prior to significant apoptosis.
Glial response. Müller glia cells were analysed using antibodies against cell type specific cytoskeletal ele-
ments: GFAP and vimentin. Under physiological conditions GFAP intermediate filaments are detectable only 
near the ILM, in the end feet of the Müller glia cells and in astrocytes of the nerve fibre layer7. Vimentin on 
the other hand stains the whole Müller cells even under control conditions28. In agreement with our previous 
study about STZ-induced diabetic retinopathy14 we found a major increase in GFAP expression, with a complete 
staining throughout the full length of Müller cells but no evident change in vimentin labelling in the ZDF retinas 
compared to controls. The change in GFAP labelling was prominent all over the retina. Results are demonstrated 
on Fig. 3a,e for vimentin, b and f for GFAP.
Figure 2. Comparison of the thickness of the full retina (ILM-OLM distance), the ONL layer alone, and the 
average number of nuclei in an ONL column between diabetic and lean animals. Samples were taken 250 µm, 
500 µm and 4000 µm superiorly and inferiorly from the optic nerve head. *indicate a significant increase in the 
parameters measured in diabetic specimens. There was no significant difference in the number of nuclei in the 
ONL columns in any region examined. ILM: inner limiting membrane, OLM: outer limiting membrane, ONL: 
outer nuclear layer, ON: optic nerve, *p < 0.05.
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To analyse the microglia population the slides were labelled with WGA lectin and Isolectin B4. With WGA, 
besides the dominant labelling of blood vessels and the interphotoreceptor matrix of rods, we found several star 
shaped cells exclusively in the inner retina with long branching processes typical for resting microglia (Fig. 3c,g). 
No noteworthy difference was detected between diabetic and lean rats. Isolectin B4 (besides a faint but visible 
staining of cones and the prominent staining of blood vessels) also stained a population of microglia-like cells 
with similar number and morphology without any detectable change under diabetic conditions (not shown). 
With these two lectins - labelling mostly long processes but not the complete cell body of microglia cells - the pre-
cise quantification was impossible. In order to ensure that all microglia cells are labelled and counted, we stained 
some sections with Iba1 antibody, recognizing both resting and activated microglia cells. The overall number of 
cells per sections were calculated and revealed an approximately 2.5-fold increase in diabetic specimens com-
pared to controls (111 ± 8.6 in control vs. 297.8 ± 37.5 cells per section in diabetic specimens, p: 0.0002). The 
cells showed no evident sign of microglia activation (Fig. 3d,h): there was no change in overall morphology and 
labelled cells never appeared in the ONL. Recent publications however indicate that in the retina microglia acti-
vation may not necessarily coincide with altered morphology29.
Photoreceptor degeneration. Different cone populations can be distinguished with immunocytochem-
istry. In control rat retinas, the majority of cones are middle wavelength sensitive (M-cones), while approximately 
ten percent belongs to the short wavelength sensitive type (S-cones)30, 31. A few cones in the peripheral retina 
contain both photopigments (dual cones)32.
There was no difference in labelling intensity of M- and S-cones in diabetic specimens (Fig. 4c) compared to 
controls (Fig. 4a). Regarding morphology however, there was a remarkable outer segment degeneration, mani-
fested by the fragmentation of outer segments with thin stalks connecting the fragments (Fig. 4c – some of the 
fragmented outer segments are marked by arrows). As an advantage of using relatively thick frozen sections, with 
a thickness of approximately 20 micrometres – the range that equals the length of the cone outer segments – it was 
relatively easy to follow most outer segments completely in all sections with confocal microscopic scans, even if 
the section was not fully vertical. Checking concomitant focal planes, it was possible to ensure that the fragments 
of the degenerated outer segments belonged to the same element. Representative confocal stacks from lean and 
diabetic retinas are available for download at https://drive.google.com/open?id=0ByKM9hoX0qWxRV8zZG-
t1ZDcxSUU. The majority of M-cones were affected all over the retina. This is in full agreement with our previous 
results obtained in STZ-induced diabetic rats13. In order to further analyse the outer segment changes in ZFD 
rats, we applied an antibody against cone arrestin - a functional protein in the inactivation phase of the photot-
ransduction cascade. Although the degenerated profile of cone outer segments was evident, we found no change 
in the staining intensity of this antibody (Fig. 5a,b).
Figure 3. Glial responses in diabetes. Upper row shows control, lower row diabetic specimen. Müller glia cells 
were analysed using vimentin and GFAP antibodies. A marked increase in GFAP expression (b,f) but no major 
change in vimentin (a,e) labelling was evident. Microglia activation was analysed with WGA lectin and Iba1 
antibody. Besides microglia cells WGA (c,g) labels the interphotoreceptor matrix of rods, blood vessels, and the 
plexiform layers. The microglia cells stained showed similar morphology (arrows on c and g, the same cells on 
high magnification on the insets). With Iba1 antibody (d,h) an approximately 2.5-fold increase in the number 
of microglia cells was detectable in diabetic specimen without evident signs of microglia activation. DAPI is 
used as a nuclear staining (a–c and e–g in blue). PR: photoreceptor layer, ONL: outer nuclear layer, INL: inner 
nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell layer. Bar: 20 μm and 10 μm for the insets.
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Due to the prominent outer segment degeneration, the precise quantification of cone numbers on sections 
was not feasible. We only attempted counting on a limited number of sections. The results of M-cone counts in 
different retinal regions were given in detail in Fig. 4i. Due to the low number of sections and the uncertainty of 
outer segment recognition no statistical evaluation was performed. We can rule out however any major loss of 
cone photoreceptor cells.
In the peripheral retina, there was a sharp increase in the number of dual cones, where almost all cones 
coexpressed both M- and S-opsins in diabetic animals (Fig. 4e–h). A few dual cones were also detected in cen-
tral regions in diabetic specimens, albeit in much smaller numbers. Dual cones were reliably identified with all 
antibody combinations used.
Figure 4. Outer segment degeneration of rods and cones with an increase in the number of dual cones in the 
peripheral retina in diabetes. Cone populations were labelled by AB5405 polyclonal antibody recognizing 
M-opsin (a,c and e–h, in green) and OS-2, staining S-opsin (a,c, e–h, in red). Note the evident outer segment 
degeneration in diabetes (c, arrows) compared to controls (a), without any major decrease in the number 
of M-cones in any region examined (i). In the peripheral retina of lean ZDF rats only a few (e,f), while in 
diabetic specimens near the ora serrata almost all M-cones co-label with S-opsin (g,h). Some dual cones are 
marked by arrowheads. Rod outer segments labelled with anti-rhodopsin antibody (in green) also show severe 
morphological degeneration in diabetic specimens (d) compared to controls (b). On the same pair of pictures 
a visible decrease in the intensity of RPE-65 staining of the pigmented epithelium is also evident (in red). DAPI 
was used for nuclear staining (in blue). RPE: retinal pigment epithelium, OS: outer segment, IS: inner segment, 
ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer. Bar: 10 μm for (a–d) and 15 μm 
for (e–h).
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Figure 5. Elements of the phototransduction cascade and cone interphotoreceptor matrix in diabetes. Severe 
outer segment degeneration of cones was also evident with cone arrestin antibody ((a): control,  
(b): diabetic specimens), while PNA staining of the interphotoreceptor matrix of the cones did not show any 
major difference ((c): control, (d): diabetic). When comparing the expression of the regulatory elements of 
the rod phototransduction cascade, only minor differences were detected. Whereas in most retinal regions the 
expression pattern was similar to control (e), with rod arrestin a protein mislocalization to the perikarya was 
detectable (f) but only in some regions showing the most deteriorated outer segment morphology. No such 
change was evident for rod transducin ((g): control, (h): diabetic). OS: outer segment, IS: inner segment, ONL: 
outer nuclear layer, OPL: outer plexiform layer, Bar: 20 μm.
www.nature.com/scientificreports/
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Rod morphology was examined with a polyclonal anti-rhodopsin (AO) antibody. Like in cones the morphol-
ogy of rod outer segments seemed to be degenerated in almost all regions examined (Fig. 4b,d). Also in case of 
rods, checking single confocal planes from the stacks made it possible to decide if rod outer segments were degen-
erated or not - irrespectively whether they were aligned properly or obliquely - without any difficulty. Examples of 
single confocal plane images from healthy and degenerated outer segments are shown in Supplementary Fig. S6. 
Alternatively, rods could also be labelled with antibodies against rod phototransduction regulatory proteins: 
recoverin (Fig. 6a,e), rod arrestin (Fig. 5e,f) and rod transducin (Fig. 5g,h). In contrast to the altered morphol-
ogy there was only a slight change in the distribution and staining intensity of regulatory proteins. In case of rod 
Figure 6. Cone and rod bipolar cells in diabetes. Cone and rod bipolar cells were analysed using anti-recoverin 
(a,e,j in green) and anti-PKC-α (b, f in red) antibodies, respectively. For orientation cell nuclei were labelled 
with DAPI-staining (c,g,k). Merged view: d, h. Both bipolar cell types including ON and OFF cone bipolar 
subtypes showed normal morphology in diabetes (second row) compared to controls (upper row). PKC-α 
also labelled at least one population of amacrine and displaced amacrine cells (arrowheads in b and f), while 
recoverin also stained all photoreceptor cells and a low number of cells in the ganglion cell layer with cone 
or rod like nuclear morphology (arrows in j and k). Quantitative analysis showed no evident change in the 
number of recoverin positive cells in any region of the retina (i). There was an increase in the number of PKC-α 
positive, displaced amacrine cells in the GCL in the superior central and mid-peripheral retinal regions (m). In 
contrast the number of PKC-α positive amacrine cells in the INL decreased or showed no change in diabetes (l). 
Significant differences (p < 0.05) were labelled with *. ONL: outer nuclear layer, INL: inner nuclear layer, IPL: 
inner plexiform layer, ON and OFF: sublayers of the IPL, GCL: ganglion cell layer. Bar: 20 μm (a–h) and 10 μm 
for j and k.
www.nature.com/scientificreports/
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arrestin we found a detectable mislocalization of the protein to perikarya in diabetic specimens, restricted to the 
morphologically less preserved regions.
The possible changes in glycosylation of the interphotoreceptor matrix proteins were assessed with PNA 
(Fig. 5c,d) and WGA (Fig. 3c,g) lectins. Unlike in STZ-induced Sprague-Dawley T1D rats13, in this case no 
change was detectable.
Retinal pigment epithelium. RPE-65 labels isomerohydrolase enzyme located in the pigmented epithe-
lium. In a previous report13, visible change in RPE-65 activity along with a significant change in RPE thick-
ness was reported in Wistar rats. In ZDF rats, although no precise quantification of thickness was attempted, a 
decrease in immunostaining was prominent (Fig. 4b,d).
Bipolar cells. Besides the photoreceptors both the ON and OFF cone bipolar cells can be labelled with recov-
erin antibody33. Comparing diabetic and control retinal sections recoverin immunocytochemistry showed no 
major change in either the morphology (Fig. 6a,e) or the number (Fig. 6i) of these cell types stained. Details of the 
statistical analysis are given in Table S7. We also detected a minor recoverin-positive population amongst the gan-
glion cells with dendrites branching exclusively in the ON sublayer of the inner plexiform layer (IPL) (Fig. 6j,k). 
Literature and our own data indicate that these cells also contain rod or cone opsins34, 35. Although no precise 
quantification was attempted, these cells seem to be present with similar morphology and equally low numbers 
in diabetic specimen as well.
With PKC-α antibody we did not find any major qualitative difference in the rod bipolar cell population 
(Fig. 6b,f). Due to the overlapping cell bodies and their extremely high number, no quantification was attempted 
for rod bipolar cells.
Changes in amacrine cells. Due to their diversity, amacrine cells can be detected with several different 
antibodies labelling various subpopulations.
Besides rod bipolar cells there was at least one amacrine and a displaced amacrine cell population also 
detectable with the PKC-α antibody (Fig. 6b,f). Regarding these two PKC-α positive amacrine cell popula-
tions we detected a significant increase in the number of displaced amacrine cells in the superior central and 
mid-peripheral regions in diabetic specimens compared to controls (Fig. 6m). A decrease in the number of 
PKC-α positive amacrine cells in the inner nuclear layer (INL) could also be observed in one region (Fig. 6l). 
Details of the statistics, with the appropriate p values are listed in Supplementary material, Tables S8 and S9.
Parvalbumin stains dominantly AII amacrine cells, along with a few wide field amacrine cells, a population 
of bipolar cells and a few cells in the ganglion cell layer (GCL)36. We detected a moderate or markedly decreased 
staining intensity for all labelled cell types and incomplete arborisation in diabetic specimens (Fig. 7a–c). Beside 
the change in staining intensity, no difference in the number of labelled AII amacrine cells was detectable for the 
majority of the retina; except for the superior peripheral and inferior mid-peripheral counting frame, in which the 
decrease was significant (Fig. 7d). Details of the statistical analysis are given in Supplementary material, Table S10.
Calretinin is a frequently used marker staining mostly amacrine and displaced amacrine cells with processes 
terminating in three distinct layers of the IPL. A few ganglion cells can also be labelled37. Comparing control and 
diabetic retinas, no difference was evident in staining intensity (Fig. 8a,d) and in the number of stained elements 
located in the INL or GCL (Fig. 8g,h). Details of the statistical analysis, with the appropriate p values are listed in 
Tables S11 and S12. Only a slight disorganization of the IPL sublayers was detectable (Fig. 8d) in diabetic speci-
mens, however it was not a consistent finding and was restricted to a few retinal regions only.
Tyrosine hydroxylase labels dopaminergic amacrine cells38. A prominent decrease in staining intensity was 
detectable in diabetic rats (Fig. 8b,e), furthermore there was a significant change in the number of stained ele-
ments (7.9 ± 1.7 labelled cell bodies per section in control and 6.3 ± 2.2 in diabetes, p: 0.045).
Choline acetyltransferase labels two populations of starburst amacrine cells with processes terminating in the 
ON and OFF sublamina of the IPL, respectively. Although no precise quantifications were performed, diabetes 
does not seem to cause any major qualitative and quantitative change in their distributions (Fig. 8c,f).
Horizontal cells. The antibody against calbindin stains horizontal cells and a few cells in the INL and GCL 
under control conditions36. Comparing sections of diabetic and lean specimens (Fig. 8a,d), we did not find any 
qualitative or significant quantitative changes in calbindin labelling. The number of horizontal cells per section 
was 116.3 ± 13.9 in lean vs. 125.7 ± 14.8 in diabetic specimens (p: 0.06).
Ganglion cells. Many markers used in our study labelled a smaller or larger population of ganglion cells 
including recoverin, calretinin, parvalbumin, cone arrestin, rod arrestin and rod transducin. Although no precise 
counting was performed specifically for the ganglion cells with most of the antibodies, no noticeable difference 
was evident. In order to estimate the possibility and the rate of overall ganglion cell loss, we used an antibody 
against Brn-3a (Fig. 9a,b). Literature data indicate that the majority of ganglion cells can be labelled with this 
antibody39. We calculated the total number of labelled cells per sections comparing diabetic and control speci-
mens (n = 4 sections from each retina, from 4 specimens from each group) and observed no significant difference 
(319.4 ± 49.8 cells per section in lean vs. 346.5 ± 51.2 cells per section in diabetic specimens, p: 0.23).
Discussion
Although T2D rat models such as ZDF, OLETF, SDT rats etc. were established decades ago (reviews:16, 40), ocular 
lesions were addressed on these models only by few reports, in which mostly the pathology of retinal capillar-
ies was studied in details. In 6–7 months old ZDF rats, retinal capillaries were reported to be hypercellular and 
basement membranes thicker than in lean rats of the same age41. Elevated expression of inflammatory cytokines, 
oxidative stress markers and VEGF were also demonstrated in 14 weeks old ZDF rats42, while the gene expression 
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of these factors were studied at 32 weeks of age43. Ischemic features of the human diabetic retina like acellular cap-
illaries and pericyte loss were absent in 6-7 months old ZDF rats40 but appeared at later stages examined (33–34 
postnatal weeks:44; 32 postnatal weeks:43). Apart from the capillary structure, histopathological data on ZDF rat 
retina in literature are extremely sparse. There are reports on Müller glia activation45, increased rate of apoptosis 
already in 19 weeks old ZDF rats46 or contradictorily on no change in retinal thickness and apoptosis rate even at 
23 weeks of age45.
To fill this gap, in this report we gave a detailed immunocytochemical analysis on the histopathology of both 
glial and neural cell types of ZDF rat retinas. We used the same palette of antibodies that we had utilized pre-
viously on STZ-induced diabetic models13, 14 in order to compare T1D and T2D directly with the same meth-
odology and to draw possible conclusions about the factors contributing to the alterations detected. Numerous 
metabolic differences exist between the early stages of type 1 and type 2 diabetes (e.g. opposite changes in insulin 
levels, insulin resistance, obesity, hyperlipidaemia etc. – ref. 47) that may all have effect on retinal histopathology. 
Therefore our original assumption was that T2D rat models would show differences in the type of retinal cells 
affected or in the rate of damage.
However, the data presented here reveal a surprising similarity of the pathology of T1D and T2D rat models 
examined. Both models feature a prominent glia activation, outer segment degeneration for almost all M-cones 
and rods, changes in cone-opsin expression patterns, a decreased expression of RPE-65 in pigment epithelial cells 
and changes in the labelling patterns and the morphology of some amacrine cell types. We can thus conclude that 
despite the different evolution of the two types of the disease, the neuroretinal cells effected are the same in both 
subtypes of diabetes.
Furthermore, Müller glia activation with a prominent upregulation of GFAP expression was accompanied by 
a downregulation (T1D – ref. 14) or unaltered (ZDF) expression of vimentin intermediate filaments. This opposite 
Figure 7. A decrease in the staining intensity and arborisation of parvalbumin stained AII amacrine cells. 
Parvalbumin (in red) stains mostly AII amacrine cells (arrows), a population of bipolar cells (arrowheads) and a 
few cells in the GCL. Compared to controls (a), there was a decrease in the staining intensity and arborisation of 
AII amacrine cells which was prominent in some regions (c), but less well visible in others (b). In most regions, 
there was no detectable change in the number of stained elements. Precise quantification (d) revealed a decrease 
only in the superior peripheral and inferior mid-peripheral regions (*: p < 0.05). DAPI is used as a nuclear 
staining on a, b and c. PR: photoreceptor layer, ONL: outer nuclear layer, INL: inner nuclear layer, IPL: inner 
plexiform layer, GCL: ganglion cell layer. Bar: 20 μm.
www.nature.com/scientificreports/
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alteration pattern seems to be specific for diabetic conditions14. In most other pathologies both GFAP and vimen-
tin is upregulated48. Under cell culture conditions similar expression pattern can be detected experimentally, if 
Müller glia cells are co-cultured with activated microglia cells49. So in this study we specifically examined the 
microglia response in diabetes and detected an increase in their number – a situation mimicking the published 
culture conditions. Whether this unusual Müller glia activation has any specific role in the pathophysiology of the 
disease requires further investigations.
Considering the metabolic differences between the early stages of T1D and T2D (e.g. opposite changes in 
insulin levels, insulin resistance, obesity, hyperlipidaemia47) the similarity of their neuroretinal pathology is 
rather surprising, with special respect to the near equal rate of photoreceptor outer segment degeneration in both 
models. Although in our previous work13 outer segment degeneration of rods was also confirmed by electron 
microscopy, here – due to the complex nature of the study – sacrificing sections for this purpose was not possible. 
Figure 8. Staining patterns for calbindin, calretinin, tyrosine hydroxylase and choline acetyltransferase (ChAT) 
antibodies in lean (upper row) and diabetic rat retinas (lower row). Calbindin (a,d, in red) stains horizontal 
cells, and a few cells in the INL and GCL. Calretinin (a,d, in green) is a frequently used marker for some 
ganglion cells, amacrine and displaced amacrine cells, with processes terminating in three distinct layers of 
the IPL. No change in staining intensity or in the number of stained cells was evident for these two antibodies. 
Quantification for calretinin positive cells are given in g and h. Antibody against tyrosine hydroxylase (b, e, in 
red) labels dopaminergic amacrine cells. A slight decrease in staining intensity was detectable in diabetes (e). 
ChAT antibody (c,f in red) labels mostly cholinergic starburst amacrine cells, along with some axons in the 
nerve fibre layer (arrowheads) and possibly some ganglion cells also. No change was evident in diabetes. DAPI is 
used as a nuclear staining. ONL: outer nuclear layer, INL: inner nuclear layer, GCL: ganglion cell layer, ON and 
OFF: sublayers of the IPL. Bar: 20 μm.
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However, the relatively thick sections prepared for confocal microscopy, allowed us to follow individual outer 
segments and confirm degeneration on the stacks or on single confocal planes. This technique was especially 
useful in case of cones, for which outer segment degeneration is almost impossible to determine on electron 
microscopic sections, due to their low number in rodents (cones comprise less than 1% of all photoreceptors in 
the rat retina – refs 30 and 31).
It has been long proposed that insulin is one of the key factors in the development and surviving of the cone 
and rod outer segment23, 24. Yet, despite the initially opposite changes in insulin levels, no major difference was 
evident in morphology (at least) in the diabetic stage examined. This can be explained by two distinct proposi-
tions. On the one hand rats were insulinopenic approximately from postnatal week 2018 - for about 12 weeks in 
our experiment - and this relatively long period might have been enough to diminish the possible protective effect 
(if any) of early elevated insulin levels. Alternatively, hyperglycaemia alone might be sufficient to induce most 
pathologic alterations of the disease, while altered insulin signalling plays a less decisive role. Hyperglycaemia has 
also been suggested by others as a major casual factor in diabetic retinal and neural degeneration that may con-
tribute to the development of pathological alterations through several possible mechanisms, like polyol pathway, 
oxidative stress, non-enzymatic glycation, oedema formation etc. (For review see refs 27 and 50).
To develop diabetes in animals, some kind of chemical induction (e.g. streptozotocin) is a technique often 
applied. When studying diabetic models, especially the neural effects of diabetes, one should always consider that 
not only the metabolic changes but also the chemical itself used for the induction may give rise to some of the 
neural alterations51. Our results presented here, with histological pictures similar to T1D models13, 14, exclude any 
major role of STZ in the development of the detected pathologies.
There are few minor and mostly quantitative differences detected by us between the animal models of T1D 
and T2D which may be due to the different duration of hyperglycaemia. In our study, STZ-induced rats were 
analysed three months after the induction, with continuously high glucose levels (>20 mmol/l) throughout 
the observation period. In ZDF rats blood levels were in the same range for approximately five months (from 
12th to 32nd weeks), with moderately high values between the 7th and 12th weeks. In STZ-induced diabetes, we 
detected a patchy appearance of Müller glia activation and AII amacrine cell degeneration. In contrast, in ZDF 
rats Müller glia cells were activated all over the retina, while parvalbumin showed a highly-degenerated profile for 
the majority of the retina. Also, whereas no decrease in numbers could be confirmed for any cell types counted 
in the STZ-induced model, in ZDF we detected a small but already significant decrease in the number of some 
of the elements counted (AII amacrine cells, dopaminergic amacrine cells), sometimes restricted to some retinal 
regions. As we proposed earlier14 the initially patchy degeneration later may appear all over the retina with the 
progression of the disease and finally the degenerated cells begin to be eliminated. The results presented here are 
certainly in line with this proposition.
There are a number of additional factors known to occur in diabetes, like impaired autoregulation52 oxidative 
stress53–55 and inflammatory citokine expression42, 43 – that were not examined in detail in the study. We can not 
rule out therefore, that these factors also contribute to the development of the detected alterations.
Apoptosis is one of the earliest and most often documented features of diabetic retinopathy, present in human 
diabetic patients56 as well as in practically all animal models44, 57, 58. Apoptotic cells were detectable related to the 
vasculature44 and amongst neural elements56 eventually leading to the thinning of the neural retinal layers57. We 
must emphasize that despite a slight but already detectable decrease in the number of certain cell populations, at 
this stage examined there was no major loss of cells as proven clearly by the cell counts, and the lack of significant 
Figure 9. There was no major change in ganglion cell staining detected by Brn-3a antibody in control (a) and 
diabetic (b) specimens. DAPI is used as a nuclear staining. ONL: outer nuclear layer, INL: inner nuclear layer, 
GCL: ganglion cell layer. Bar: 20 μm.
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increase in the number of apoptotic bodies or retinal thickness. This is in agreement with the results on 23 weeks 
old animals of Johnson et al.45. but contrary to other observations46 reporting an increase in the number of apop-
totic cells already in 19 weeks old ZDF rats. The reason for this discrepancy is currently unknown but may be 
related to the differences in animal care, number of sections examined and reagents used. The lack of detectable 
increase in TUNEL-positive elements and reduction in retinal thickness clearly indicate that the histological 
alterations presented here in ZDF rats also precede significant retinal cell loss – as well as in STZ-induced diabetic 
rats13, 14.
In our previous reports on T1D rat model13, 14 we concluded that the histological alterations described by us 
may be related to some of the early detectable symptoms of diabetic patients, like ERG changes and colour vision 
defects5, 59. In our present study, we also found similar signs of degeneration in the rod pathway, like rod outer 
segment degeneration, rod arrestin mislocalization and changes in the morphology and number of AII amacrine 
cells that - in theory - may all contribute to the alteration of scotopic ERG reported in diabetic patients59, 60 and 
in animal models45, 60. Colour vision defects61, 62 and photopic ERG changes63 can be related to changes in cone 
opsin expression pattern and M-cone outer segment degeneration. Changes in oscillatory potentials45 may be the 
ERG manifestations of amacrine cell dysfunctions – from which AII amacrine cells, dopaminergic amacrine cells 
and PKC-α positive amacrine cells certainly show alterations in ZDF rats, as well as STZ induced diabetic rats. 
The relationship between histopathology described by us and functional alteration thus seems to be a reasonable 
conclusion but at this stage, we lack direct evidence.
Available ERG data from ZDF rats in literature are extremely sparse. Data published from 8 to 22 weeks old 
animals show an increase in a-wave amplitude and maximum slope under scotopic conditions45. These changes 
are different from those in human patients and type 1 diabetic rats. Similarly to other models and human data 
however they show delay in oscillatory potentials45. No electrophysiological data are available in literature from 
later stages that could correspond to our study. Further studies are required to obtain a more detailed picture 
about the possible connection between functional changes and histological alterations.
In summary, we report the first detailed description on the histopathology of the neural retina of the ZDF rats, 
one of the most commonly used T2D model. We present alterations similar to those detected in STZ-induced 
T1D rats and conclude that the cell types effected are the same in both types of the disease, and hypothesize that 
the results presented could underlie the functional alterations detected in human patients and animal models. 
These findings support the idea that both rat models are beneficial for studying early diabetic alterations of the 
neuroretina.
Materials and Methods
Animal handling. All procedures of the present study were performed in concordance with the Association 
for Research in Vision and Ophthalmology (ARVO) statement for the Use of Animals in Ophthalmic and Vision 
Research and were approved by the local Ethical Committee for Animal Experimentation of the Semmelweis 
University and by the Animal Health and Animal Welfare Directorate of the National Food Chain Safety Office of 
the Hungarian State (number of approval: 22.1/1162/3/2010).
Experiments were carried out on ZDF inbred rats, where T2D and related complications develop due to a 
leptin receptor gene mutation and a special diet. Homozygous recessive males (fa/fa) develop obesity, fasting 
hyperglycaemia and T2D. Homozygous dominant (+/+) and heterozygous (fa/+) genotypes remain normogly-
cemic (ZDF lean). ZDF rats (n = 8) and ZDF lean controls (n = 8) were obtained from Charles River Laboratories 
(Sulzfeld, Germany) at the age of 6 weeks, housed in a room with constant temperature (22 ± 2 °C) under a 
12-12 h alternating light-dark cycle. Rats were supplied with a special diet (Purina 5008 as recommended by the 
supplier) and water ad libitum. Blood glucose levels were checked at the 7th week, and every five weeks thereafter. 
Body weights were measured prior to anaesthesia. At the age of 32 weeks, anaesthesia was induced and main-
tained with isoflurane (3–5% and 1.5–3%, respectively). A drop of blood was collected from the tail vein for blood 
glucose determination carried out with a digital glucose meter and test strips (Accu-Chek® Sensor, Roche Inc., 
Mannheim, Germany). Rats were tracheotomized, intubated, artificially ventilated and invasive hemodynamic 
measurements were carried out using a Millar microcatheter (Millar Inc, Huston, Texas, USA), as described else-
where64. Detailed results of the hemodynamic measurements will be given in another report.
To remove erythrocytes from tissues an in vivo perfusion was performed. After opening the thoracic cavity 
and dissecting the inferior vena cava, a total volume of 40 ml oxygenated Ringer solution (37 °C) was infused into 
the left ventricle through the apex of the heart with a speed of 8 ml/min. All animals were euthanized by exsan-
guination and decapitated. The eyes were removed and placed into fixative within 10 minutes after euthanasia.
Tissue preparation and immunohistochemistry. Oriented and enucleated eyes were cut at the ora ser-
rata, then the cornea, lens and vitreous body were removed, finally the posterior eyecups were immersed in freshly 
prepared fixative solution (4% paraformaldehyde diluted in 0.1 M phosphate buffer [PB, pH 7.4]), for two hours 
at room temperature (RT). After extensive rinsing in 0.1 M PB, cryoprotection (in 30% sucrose diluted in 0.1 M 
PB) was applied overnight at 4 °C, then the eyecups were embedded in tissue-embedding medium (Shandon 
Cryomatrix, Thermo Scientific, UK). 20 μm thick cryosections were cut vertically and stored at −20 °C until use.
Immunohistochemical procedures were carried out on cryosections according to protocols previously pub-
lished by our laboratory35. In brief, prior to incubation with primary antibodies, to block nonspecific staining, 
sections were treated with 1% bovine serum albumin diluted in 0.1 M phosphate buffered saline (PBS, pH 7.4) 
with additional 0.4% Triton X-100 (Sigma-Aldrich Kft, Budapest, Hungary) for 2 hours at RT. Primary antibodies 
(details are listed in Table 1) were applied on sections overnight at 4 °C. After repeated rinsing, species-specific 
fluorescent probes (Alexa 488 or Alexa 594 conjugates, 1:200, Life Technologies, Carlsbad, CA) were applied for 
2 hours at RT. Cell nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole, Sigma-Aldrich Kft, 
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Budapest, Hungary). Sections with the primary antibodies omitted were used as negative controls. Most of the 
antibodies applied have been tested and validated in rat retinas previously13, 14, 35.
Lectin histochemistry was also applied on a few sections. List of the lectins used, with the staining character-
istics are given in Table 2. Lectins were either used in a biotinylated or fluorescent isothiocyanate (FITC, in case 
of isolectin B4) conjugated form (2 h, RT) and were detected with streptavidin linked Alexa dies, or Alexa 488 
conjugated anti-FITC antibody (1:200, Life Technologies, Carlsbad, CA).
Measurement of retinal thickness. To assess the effect of diabetes on the thickness of the retina, the dis-
tance between the outer and inner limiting membranes (ILM-OLM), and the thickness of the outer nuclear layer 
(ONL) alone was measured at six given locations (250 and 500 μm (central values), as well as 4000 μm (periph-
eral values) from the optic nerve head in both superior and inferior directions), on four sections per each retina 
derived from four specimens from each group.
In the ONL, nuclei are typically arranged in columns on well oriented sections. To further estimate the num-
ber of photoreceptor cells, additionally we also counted the number of nuclei in the ONL in at least three columns 
per each location parallel with the thickness measurements.
Antibodies (name, clone 
and cat. number) Source
Working 
concentration Host and type
Epitope specificity or 
labelling pattern in rats Reference




Budapest, Hungary 1:1000 mouse monoclonal






MA, USA 1:10000 mouse monoclonal Müller cells
28
Iba1, #019-19741 Wako Chemicals Inc, USA 1:500 rabbit polyclonal microglia
67
Rb X opsin red/green, 
#AB5405
Millipore, Billerica, 
MA 1:1000 rabbit polyclonal M-cone opsin
68
anti-opsin blue, #AB5407 Millipore, Billerica, MA 1:1000 rabbit polyclonal S-cone opsin
69
COS-1 produced in our laboratory 1:50 mouse monoclonal M-cone opsin
70
OS-2 produced in our laboratory 1:5000 mouse monoclonal S-cone opsin
70
cone arrestin, #AB15282 Millipore, Billerica, MA 1:1000 rabbit polyclonal cone photoreceptors
71
rhodopsin (AO) produced in our laboratory 1:1000 rat polyclonal rod photoreceptors
70
recoverin





cone bipolar cells, rod and 




generous gift of Igal 
Gery, National Eye 
Institute, Bethesda, 
MD, USA
1:400 rabbit polyclonal rod photoreceptors 72
rod transducin, #AB74059 Abcam, Cambridge, UK 1:300 rabbit polyclonal rod photoreceptors
73
retinal pigment epithelium-
specific 65 kDa protein 
(RPE-65), #MAB5428
Merck Kft., Budapest, 










rod bipolar cells, few 






Budapest, Hungary 1:300 mouse monoclonal
AII and some widefield 
amacrine cells, a small 
number of bipolar and 
ganglion cells
36
calretinin, #AB5054 Millipore, Billerica, MA, USA 1:2500 polyclonal rabbit
amacrine cells in the IPL, 
amacrine and ganglion cells 
in the GCL
37, 76
tyrosine hydroxylase (TH), 
#MAB5280
Millipore, Billerica, 





MA, USA 1:200 goat polyclonal cholinergic amacrine cells
77
calbindin D28k, #300 Swant, Marly, Switzerland 1:200 mouse monoclonal
horizontal cells, few 







1:500 goat polyclonal ganglion cells 79
Table 1. Primary antibodies used in the study.
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Only vertical cryosections at the level of the optic nerve were analysed using a Zeiss Axiophot (Carl Zeiss, 
Oberkochen, Germany) microscope with a 40x (NA: 1,4) oil immersion objective.
Cell counting. Unless otherwise indicated cell counting was performed on 20 µm thick vertical sections 
(n = 4 sections per specimen) taken from both diabetic (n = 4) and lean (n = 4) rats. For cell counting only the 
sections going through the optic nerve head were selected, sections taken from the same specimen were approx-
imately 100 µm away from each other in the temporo-nasal direction.
In case of horizontal cells (labelled with calbindin), dopaminergic amacrine cells (labelled with TH), micro-
glia cells (Iba1) and ganglion cells (Brn-3a) the total number of the stained cells per sections were counted. For 
counting M-cones, calretinin, parvalbumin and recoverin positive elements 350 µm long central (immediately 
adjacent to the optic nerve head), mid-peripheral (approximately 3 fields – 875 µm away from the optic disc) and 
peripheral (approximately 6 fields – 1925 µm away from the optic nerve) regions were chosen in both superior 
and inferior directions. Calretinin positive cells were counted separately in the INL and GCL.
Apoptosis. To define the number of apoptotic cells terminal deoxynucleotidyl transferase deoxyuridine 
triphosphate nick end labelling (TUNEL, In situ Cell Death Detection Kit, Fluorescein; Roche Diagnostics, 
Mannheim, Germany) assay was used on complete vertical sections through the optic nerve of both diabetic 
(n = 4) and lean (n = 4) animals with 4 sections per each specimen. For negative controls, we have used sections 
incubated omitting the terminal transferase enzyme, while positive control sections were pre-incubated with 
DNAse I prior to performing the TUNEL reaction.
Statistical analysis. All data were represented as mean ± standard deviation (SD). Statistical analysis was 
performed using R Statistical Program65. In case of body weight measurements, and counting of horizontal cells 
(labelled with calbindin), dopaminergic amacrine cells (labelled with TH), microglia cells (Iba1) and ganglion 
cells (Brn-3a) the normality of the data was tested with the Shapiro-Wilk’s test, while for comparing the deviations 
the F-test was used. To investigate the possible difference between cell numbers in the lean and diabetic groups, 
in case of normal distribution of data two-sample Student’s t-test for equal deviation and Welch test for unequal 
deviations was performed. Non-parametric data were analysed with Mann-Whitney test. P-values less than 0.05 
were considered significant.
For analysing blood glucose levels, two-way repeated measures ANOVA test, while for the statistical analysis 
of retinal- and ONL thickness, number of nuclei in the ONL, calretinin, parvalbumin and recoverin positive ele-
ments two-way ANOVA test was used with the Bonferroni post hoc test. P-values less than 0.05 were considered 
significant.
Imaging. Sections were viewed and images were recorded with a Zeiss LSM 780 Confocal System coupled 
to a Zeiss Axio Imager upright microscope, using Zen 2012 software (Carl Zeiss, Oberkochen, Germany) with 
identical setting for diabetic and lean specimens. Representative images were reconstructed with ImageJ soft-
ware66 using information of adjacent Z-stacks from 10 µm section thickness projected with maximum intensity 
projection. The final montages were created and labelling was added by Adobe Photoshop 7.0 (San Diego, CA, 
USA). Only minor adjustments concerning brightness and contrast were made parallel on some picture pairs 
(Fig. 3 insets, d,h; Figs 4e–h, 5a,b and 8b,e) to enhance the visibility of the morphologic features demonstrated.
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